Article
Gastroenterology & Hepatology
Laura E. Targownik, Charles N. Bernstein, Eric Benchimol, Gilaad G. Kaplan, Harminder Singh, Aruni Tennakoon, Zoann Nugent, Stephanie B. Coward, M. Ellen Kuenzig, Sanjay K. Murthy
Summary: Over the past two decades, the use of corticosteroids has decreased in both Crohn's disease and ulcerative colitis patients, with a more pronounced decline seen after 2007 in Crohn's disease. Potential reasons include the introduction and increasing use of biologic therapy for Crohn's disease and greater awareness of corticosteroid-related adverse events in IBD.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Multidisciplinary Sciences
Takashi Taida, Yuki Ohta, Jun Kato, Sadahisa Ogasawara, Yuhei Ohyama, Yukiyo Mamiya, Hayato Nakazawa, Ryosuke Horio, Chihiro Goto, Satsuki Takahashi, Akane Kurosugi, Michiko Sonoda, Wataru Shiratori, Tatsuya Kaneko, Yuya Yokoyama, Naoki Akizue, Yotaro Iino, Junichiro Kumagai, Hideaki Ishigami, Hirotaka Koseki, Kenichiro Okimoto, Keiko Saito, Masaya Saito, Tomoaki Matsumura, Tomoo Nakagawa, Shinichiro Okabe, Hirofumi Saito, Kazuki Kato, Hirotsugu Uehara, Hideaki Mizumoto, Yoshihiro Koma, Ryosaku Azemoto, Kenji Ito, Hidehiro Kamezaki, Yoshifumi Mandai, Yoshio Masuya, Yoshihiro Fukuda, Yoshio Kitsukawa, Haruhisa Shimura, Toshio Tsuyuguchi, Naoya Kato
Summary: This study aimed to reveal the changes in patient characteristics and the therapeutic strategies of inflammatory bowel diseases (IBD) before and after the implementation of biologics in Japan. The analysis showed that the implementation of biologics led to changes in patient characteristics and treatment preferences for IBD.
SCIENTIFIC REPORTS
(2023)
Article
Microbiology
Jonathan Wei Jie Lee, Damian Plichta, Larson Hogstrom, Nynke Z. Borren, Helena Lau, Sara M. Gregory, William Tan, Hamed Khalili, Clary Clish, Hera Vlamakis, Ramnik J. Xavier, Ashwin N. Ananthakrishnan
Summary: The intestinal microbiome plays a key role in determining responses to biologic therapy in inflammatory bowel disease. Microbial profiles can help predict clinical therapeutic success and guide the selection of optimal treatments for patients.
CELL HOST & MICROBE
(2021)
Article
Gastroenterology & Hepatology
Siddharth Singh, Herbert C. Heien, Lindsey Sangaralingham, Nilay D. Shah, William J. Sandborn
Summary: After adjusting for comorbid conditions and disease characteristics, obesity is not independently associated with an increased risk of serious infections in biologic-treated patients with IBD.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Christopher V. Almario, Welmoed K. van Deen, Michelle Chen, Rebecca Gale, Stephanie Sidorkiewicz, So Yung Choi, Nirupama Bonthala, Christina Ha, Gaurav Syal, Taylor Dupuy, Xiaoyu Liu, Gil Y. Melmed, Brennan M. R. Spiegel
Summary: This study compared the impact of IBD&me and a biologics fact sheet on shared decision-making between patients and providers. The study found no differences in shared decision-making between the two resources, and patients reported high satisfaction with both.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Multidisciplinary Sciences
Renato Sablich, Maria Teresa Urbano, Marco Scarpa, Federico Scognamiglio, Alberto Paviotti, Edoardo Savarino
Summary: In this retrospective study, VDZ was found to be superior to IFX in terms of clinical remission, drug persistency, clinical response, and steroid-free remission for the treatment of moderate-to-severe ulcerative colitis. However, VDZ group required more drug optimization compared to the IFX group.
SCIENTIFIC REPORTS
(2023)
Article
Gastroenterology & Hepatology
David Cheng, Bharati Kochar, Tianxi Cai, Christine S. Ritchie, Ashwin N. Ananthakrishnan
Summary: This study aimed to assess the safety of different biologic agents in older patients with inflammatory bowel diseases (IBDs) and found that ustekinumab and vedolizumab were associated with lower rates of infection-related hospitalizations compared with anti-TNF therapy, particularly for patients with high comorbidity burden.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Medicine, General & Internal
Carla J. Gargallo-Puyuelo, Viviana Laredo, Fernando Gomollon
Summary: Thiopurines play a crucial role in the treatment of IBD, but there are still unresolved issues regarding their efficacy and safety. Personalized therapy based on pharmacogenomics and genetic polymorphisms of metabolizing enzymes may help prevent side effects. Factors such as age, ethnicity, and viral infections also influence the outcomes of thiopurine therapy.
FRONTIERS IN MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Madeline Alizadeh, Osman Ali, Raymond K. Cross
Summary: Current, former, and nonsmokers have similar rates of biologic sequencing in patients with Crohn's disease. However, smoking remains a well-established risk factor for poor health outcomes, and efforts should be made to counsel patients to quit. Further research is needed to stratify patient risk based on tobacco exposure.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Nicholas P. McKenna, Scott R. Kelley, Katherine A. Bews, Kevin T. Behm, Kellie L. Mathis
Summary: This study found that laparoscopic surgery for enterovesical fistula in patients with Crohn's disease requiring surgery is safe, with similar morbidity to open repair and a shorter length of stay. Preoperative biologic exposure does not affect surgical morbidity.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Biochemical Research Methods
Alice J. Sommer, Annette Peters, Martina Rommel, Josef Cyrys, Harald Grallert, Dirk Haller, Christian L. Mueller, Marie-Abele C. Bind
Summary: Statistical analysis of microbial genomic data within epidemiological cohort studies is important for assessing the influence of environmental exposures on both the host and the host-associated microbiome. However, the observational nature of such data and the complexity of microbiome data make it challenging to discover causal associations between environment and microbiome.
PLOS COMPUTATIONAL BIOLOGY
(2022)
Article
Gastroenterology & Hepatology
Jonathan Blackwell, Sonia Saxena, Irene Petersen, Matthew Hotopf, Hanna Creese, Alex Bottle, Christopher Alexakis, Richard C. Pollok
Summary: Depression alone is not associated with subsequent development of IBD, but when accompanied by GI symptoms, it may indicate a risk for IBD.
Review
Medicine, General & Internal
Daniel C. Baumgart, Catherine Le Berre
Summary: This review discusses newer biologic and small-molecule therapies for inflammatory bowel disease, emphasizing the importance of achieving clinical and endoscopic remission as well as more precise molecular targeting of inflammatory cascades.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Bernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, Philipp Efken, Wolfgang Mohl, Thomas Krause, Martin Hoffstadt, Robert Ehehalt, Leo Trentmann, Axel Schweitzer, Petra Jessen, Petra Hartmann, Stefan Schreiber
Summary: This study aimed to compare the effectiveness of vedolizumab and anti-TNF agents in biologic-naive patients with ulcerative colitis. The results showed that after two years of treatment, vedolizumab resulted in higher remission rates than anti-TNF agents.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Neil Chanchlani, Simeng Lin, Marcus K. Auth, Chai Leng Lee, Helena Robbins, Shi Looi, Senthil Murugesan, Tom Riley, Cathryn Preston, Sophie Stephenson, Wendy Cardozo, Sunil A. Sonwalkar, Mohammed Allah-Ditta, Lynne Mansfield, Dharmaraj Durai, Mark Baker, Ian London, Emily London, Sanjay Gupta, Alex Di Mambro, Aisling Murphy, Edward Gaynor, Kelsey D. J. Jones, Andrew Claridge, Shaji Sebastian, Sankaranarayanan Ramachandran, Christian P. Selinger, Simon P. Borg-Bartolo, Paul Knight, Michael B. Sprakes, Julie Burton, Patricia Kane, Stephanie Lupton, Aimee Fletcher, Daniel R. Gaya, Roghan Colbert, John Paul Seenan, Jonathan MacDonald, Lucy Lynch, Iain McLachlan, Stephanie Shields, Richard Hansen, Lisa Gervais, Mwansa Jere, Muhammad Akhtar, Karen Black, Paul Henderson, Richard K. Russell, Charlie W. Lees, Lauranne A. A. P. Derikx, Melanie Lockett, Frederica Betteridge, Aminda De Silva, Arif Hussenbux, John Beckly, Oliver Bendall, James W. Hart, Amanda Thomas, Ben Hamilton, Claire Gordon, Desmond Chee, Timothy J. McDonald, Rachel Nice, Marian Parkinson, Helen Gardner-Thorpe, Jeff R. Butterworth, Asima Javed, Sarah Al-Shakhshir, Rekha Yadagiri, Sebrene Maher, Richard C. G. Pollok, Tze Ng, Priscilla Appiahene, Fiona Donovan, James Lok, Rajiv Chandy, Reema Jagdish, Daniyal Baig, Zahid Mahmood, Liane Marsh, Allison Moss, Amin Abdulgader, Angus Kitchin, Gareth J. Walker, Becky George, Yuen-Hui Lim, James Gulliver, Stuart Bloom, Holly Theaker, Sean Carlson, J. R. Fraser Cummings, Robert Livingstone, Amanda Beale, Josiah O. Carter, Andrew Bell, Archibald Coulter, Jonathon Snook, Helen Stone, Nicholas A. Kennedy, James R. Goodhand, Tariq Ahmad
Summary: Regardless of drug sequence, immunogenicity to the first anti-TNF agent is associated with immunogenicity to the second anti-TNF. The introduction of an immunomodulator in patients with immunogenic treatment failure improves drug persistence.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Jean-Francois Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, Alessandro Armuzzi, Konstantinos Karmiris, Javier P. Gisbert, Peter Bossuyt, Ulf Helwig, Johan Burisch, Henit Yanai, Glen A. Doherty, Fernando Magro, Tamas Molnar, Mark Lowenberg, Jonas Halfvarson, Edyta Zagorowicz, Helene Rousseau, Cedric Baumann, Filip Baert, Laurent Beaugerie
Summary: The I-CARE study aims to evaluate the benefit-risk ratio of current therapies in IBD patients. It collected data from 10,206 patients and observed the treatment risks of anti-tumor necrosis factor and other biologic therapies, particularly the risks of cancer/lymphoma and serious infections. The results showed that different treatment regimens had varying effects on patients, and further research is needed to assess specific risks.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Oncology
Ivan Guerra, Luis Bujanda, Miriam Manosa, Isabel Perez-Martinez, Maria Jose Casanova, Luisa de la Pena, Marina de Benito, Montserrat Rivero, Pilar Varela, Lorena Bernal, Ana Carolina Franco, Yolanda Ber, Marta Piqueras, Carlos Tardillo, Angel Ponferrada, Sonsoles Olivares, Alfredo J. J. Lucendo, Pau Gilabert, Monica Sierra Ausin, Maria Bellart, Amaia Herrarte, Margalida Calafat, Ruth de Francisco, Javier P. Gisbert, Jordi Guardiola, Eugeni Domenech, Fernando Bermejo
Summary: An increased risk of lymphoma has been found in patients with inflammatory bowel disease (IBD). This study aimed to analyze the management and evolution of lymphomas in IBD patients. The majority of IBD patients had been treated with thiopurines and/or anti-TNF agents before lymphoma diagnosis, and these treatments did not impact the relapse and mortality of lymphoma.
Letter
Gastroenterology & Hepatology
Peter Malfertheiner, Francis Megraud, Theodore Rokkas, Javier P. Gisbert
Article
Biochemistry & Molecular Biology
Rosario Medina-Medina, Eva Iglesias-Flores, Jose M. Benitez, Sandra Marin-Pedrosa, Isabel Salgueiro-Rodriguez, Clara I. Linares, Sandra Gonzalez-Rubio, Pilar Soto-Escribano, Beatriz Gros, Manuel L. Rodriguez-Peralvarez, Jose L. Cabriada, Maria Chaparro, Javier P. Gisbert, Eduardo Chicano-Galvez, Ignacio Ortea, Gustavo Ferrin, Valle Garcia-Sanchez, Patricia Aguilar-Melero
Summary: Therapy with anti-TNF has transformed the treatment of Crohn's disease, but long-term efficacy is limited and adverse events can occur. This study aimed to find reliable markers to predict response to anti-TNF drugs in Crohn's disease patients. By comparing protein expression profiles in plasma samples, we identified 18 differentially expressed proteins, including vinculin, that may serve as biomarkers for short-term remission. Plasma vinculin levels, along with other factors such as baseline CD Activity Index, corticosteroid induction, and bowel resection, can predict non-short-term remission.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Montse Baldan-Martin, Maria Chaparro, Javier P. Gisbert
Summary: Inflammatory bowel diseases (IBDs) are chronic and inflammatory conditions affecting the gastrointestinal tract. Despite endoscopy being the gold standard test for assessing IBD, it is invasive and uncomfortable for patients. Therefore, non-invasive biomarkers for IBD diagnosis are urgently needed. This review summarizes proteomics and metabolomics studies in animals and humans, identifying urinary biomarkers for IBD diagnosis. Large-scale multi-omics studies with collaboration between clinicians, researchers, and industry are necessary for the development of sensitive and specific diagnostic biomarkers for personalized medicine.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Biographical-Item
Gastroenterology & Hepatology
Albert Martin-Cardona, Anna Carrasco, Maria Esteve
GASTROENTEROLOGIA Y HEPATOLOGIA
(2023)
Article
Medicine, General & Internal
Cristina Rubin de Celix, Javier Martin-de-Carpi, Gemma Pujol-Muncunill, Laura Maria Palomino, Marta Velasco Rodriguez-Belvis, Rafael Martin-Masot, Victor Manuel Navas-Lopez, Elena Ricart, Maria Jose Casanova, Alejandro Rodriguez-Martinez, Eduardo Leo-Carnerero, Alba Alcaraz, Miriam Manosa, Vicent Hernandez, Maria Consuelo Cobelas Cobelas, Cesar Sanchez, Luis Menchen, Francisco Mesonero, Manuel Barreiro-De Acosta, Nazareth Martinon-Torres, Coral Tejido Sandoval, Alicia Rendo Vazquez, Pilar Corsino, Raquel Vicente, Alejandro Hernandez-Camba, Jose Ramon Alberto Alonso, I. Alonso-Abreu, Ana Maria Castro Millan, Laia Peries Reverter, Beatriz Castro, Estela Fernandez-Salgado, M. Mercedes Busto Cuinas, Jose Manuel Benitez, Lucia Madero, Fernando Clemente, Sabino Riestra, Santiago Jimenez-Trevino, Maia Bosca-Watts, Elena Crehua-Gaudiza, Marta Calvo Moya, Jose Maria Huguet, Ester-Maria Largo-Blanco, Leticia Gonzalez Vives, Rocio Plaza, Ivan Guerra, Josefa Barrio, Laura Escartin, Erika Alfambra, Noelia Cruz, M. Carmen Munoz, Maria Guadalupe Munoz Pino, Manuel Van Domselaar, Belen Botella, David Monfort Miquel, M. Carmen Rodriguez Grau, Agustin De La Mano, Yolanda Ber, Maria Calvo Iniguez, Teresa de Jesus Martinez-Perez, Maria Chaparro, Javier P. Gisbert
Summary: This study evaluated the impact of transition on inflammatory bowel disease (IBD) outcomes and found that transition care programs improve patient outcomes after the transfer from pediatric to adult IBD units. Active IBD at the time of transfer impairs outcomes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Infectious Diseases
Olga. P. Nyssen, Pietro Pratesi, Miguel. A. Spinola, Laimas Jonaitis, Angeles Perez-Aisa, Dino Vaira, Ilaria Maria Saracino, Matteo Pavoni, Giulia Fiorini, Bojan Tepes, Dmitry. S. Bordin, Irina Voynovan, Angel Lanas, Samuel. J. Martinez-Dominguez, Enrique Alfaro, Luis Bujanda, Manuel Pabon-Carrasco, Luis Hernandez, Antonio Gasbarrini, Juozas Kupcinskas, Frode Lerang, Sinead. M. Smith, Oleksiy Gridnyev, Marcis Leja, Theodore Rokkas, Ricardo Marcos-Pinto, Antonio Mestrovic, Wojciech Marlicz, Vladimir Milivojevic, Halis Simsek, Lumir Kunovsky, Veronika Papp, Perminder. S. Phull, Marino Venerito, Lyudmila Boyanova, Doron Boltin, Yaron Niv, Tamara Matysiak-Budnik, Michael Doulberis, Daniela Dobru, Vincent Lamy, Lisette. G. Capelle, Emilijia Nikolovska Trpchevska, Leticia Moreira, Anna Cano-Catalia, Pablo Parra, Francis Megraud, Colm O'Morain, Guillermo. J. Ortega, Javier. P. Gisbert
Summary: The segmentation of patients into homogeneous groups can improve the effectiveness of eradication therapy. The study aims to determine the most important treatment strategies used in Europe and evaluate the effectiveness of first-line treatments based on year and country. The analysis found that the overall treatment effectiveness increased from 87% in 2013 to 93% in 2022, with the highest effectiveness achieved in 2022 using bismuth-quadruple therapy in Spain. Cluster analysis identified homogeneous treatment groups and assessed the effectiveness of different first-line treatments.
Meeting Abstract
Gastroenterology & Hepatology
M. Baldan-Martin, C. Rubin de Celix, M. Orejudo, L. Ortega, S. Fernandez-Tome, I. Soleto, C. Ramirez, R. Arroyo, P. Fernandez, C. Santander, J. A. Moreno-Monteagudo, M. J. Casanova, F. Casals, S. Casabona, I. Becerro, U. M. Marigorta, A. M. Aransay, D. Bernardo, M. Chaparro, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
J. Burisch, M. Zhao, S. Odes, P. De Cruz, S. Vermeire, C. N. Bernstein, G. G. Kaplan, D. Duricova, D. Greenberg, H. O. Melberg, M. Watanabe, H. S. Ahn, L. Targownik, V. E. H. Pittet, V. Annese, K. Park, K. H. Konstantinos H, M. L. Hoivik, Z. Krznaric, M. Chaparro, E. V. Loftus, P. L. Lakatos, J. P. Gisbert, W. Bemelman, B. Moum, R. B. Gearry, M. D. Kappelman, A. Hart, M. Pierik, J. Andrews, S. Ng, R. D'Inca, P. Munkholm
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
M. Calafat Sard, C. Suria, F. Mesonero, R. de Francisco, C. Yague Caballero, L. de la Pena, A. Hernandez-Camba, A. Marce, B. Gallego, N. Martin-Vicente, M. Rivero, M. Iborra, I. Guerra, M. Carrillo-Palau, L. Madero, B. Burgueno, D. Montfort, G. Torres, M. Teller, J. A. Ferrer Rosique, P. Vega Villaamil, C. Roig, A. Ponferrada, E. Betore Glaria, Y. Zabana, J. P. Gisbert, N. Alcaide, B. Camps, J. Legido, M. Gonzalez Vivo, M. M. Bosca-Watts, I. Perez-Martinez, D. Casas Deza, J. Guardiola, L. Arranz Hernandez, M. Navarro, F. Gomollon, F. Canete, M. Manosa, E. Domenech
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
P. Perez Galindo, J. M. Benitez, C. Rubin de Celix, F. Mesonero, A. Castano Garcia, M. Vicuna, L. Bernal, F. Bertoletti, C. Ramirez Castro, M. Sanchez-Azofra, L. Sanchez-Delgado, A. Ponferrada, C. Tejido Sandoval, M. Capilla, V. Laredo de la Torre, M. T. Diz-Lois, C. Duenas Sadornil, N. Garcia-Morales, M. Gonzalez-Vivo, B. Lopez-Cauce, L. Melcarne, C. Calvino-Suarez, E. Lastiri Gonzalez, P. Ramirez de la Piscina, J. P. . Gisbert, I. Perez Martinez, B. Castro, A. Cousillas, M. Manosa, D. Carpio, M. Barreiro-de Acosta
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
M. Calafat Sard, I. Pascual, P. Nos, J. Barrio, A. Gutierrez, M. D. Martin-Arranz, E. Ricart, F. Gomollon, M. Sierra Ausin, J. M. Huguet, J. Guardiola, I. Vera, P. Varela, E. Iglesias, E. Garcia-Planella, L. de Castro, M. F. Garcia Sepulcre, B. Sicilia, L. Fernandez-Salazar, X. Calvet, F. Munoz, S. Garcia-Lopez, F. Bermejo, L. Ramos, P. Martinez Montiel, R. Lorente, J. L. Cabriada, M. Piqueras, I. Marin-Jimenez, M. Esteve, F. Mesonero, E. Sese, J. P. Gisbert, L. Marquez, D. Busquets, R. Pajares, F. Canete, M. Manosa, E. Domenech
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
P. Sanz Segura, F. Gomollon, S. Garcia Garcia, M. Vela, A. Fernandez-Clotet, R. Munoz, I. Garcia de la Filia, M. Garcia Prada, J. A. Ferrer Rosique, M. J. Garcia, R. de Francisco, L. Arias, J. Barrio, I. Guerra, A. Ponferrada Diaz, J. P. Gisbert, M. Carrillo-Palau, X. Calvet, L. Marquez-Mosquera, B. Gros, F. Canete, D. Monfort, R. E. Madrigal, O. Roncero, V. Laredo, M. Montoro, C. Munoz, B. Lopez-Cauce, R. Lorente, A. Fuentes, P. Vega, D. Martin, J. Nerin de la Puerta, P. Varela, D. Casas-Deza, P. Martinez, R. Pajares, A. J. Lucendo, E. Domenech, S. Garcia-Lopez
JOURNAL OF CROHNS & COLITIS
(2023)